AbioMed.
medical devices company based in Danvers, Massachusetts, USA
- Reports this week
- 0
- Active events
- 0
- Connections
- 18
What's happening
Earlier this month
-
Abiomed is a medical device company, Maura Healey serves as the current office holder, and Mike Minogue is a candidate for state office in Massachusetts.Well supported6 reports3 developments inside
-
Mike Minogue's past professional experience as a former CEO of a medical device company was reported.Some support1 report
-
Johnson & Johnson highlights its oncology pipeline as a key growth driver.Some support1 report
One to three months ago
-
Maura Healey criticized Trump administration funding while facing a Republican primary challenger, who is the CEO of AbioMed.Some support1 report1 development inside
-
Former CEO of AbioMed, Geoff Diehl, is identified as a staunch critic of Donald Trump and a political figure.Some support1 report
-
AbioMed, based in Danvers, is subject to oversight by the state government of Massachusetts.Well supported5 reports
-
Mike Minogue gained wealth from the Abiomed sale and defended his wealth in a Boston Globe article.Well supported3 reports
-
Johnson & Johnson acquired AbioMed in 2022, and the FDA subsequently issued an early alert regarding device failure related to the acquisition.Well supported4 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around AbioMed this week
News at the entities that move AbioMed most-
Johnson & Johnson StructuralJohnson & Johnson was referenced in a recent news report concerning New York City.Moves AbioMed
-
Mike Minogue StructuralOliver crashed a vehicle in New Bedford, prompting Mike Minogue to call for him to suspend his campaign.Moves AbioMed
-
FDA StructuralFDA conducted a nationwide product recall involving toothpaste flavored with strawberry and watermelon, featuring Barbie characters.Moves AbioMed
-
Department of Health & Human Services StructuralFederal policy restricts the state of Michigan's ability to use health funds managed by the Department of Health & Human Services.Moves AbioMed
-
Massachusetts StructuralThe Administration seeks to reconsider a Massachusetts wind farm permit, potentially derailing energy legislation.Moves AbioMed
-
Maura Healey OperationalMaura Healey is proposing the temporary suspension of the state gas tax in Massachusetts, while AAA tracks average prices.Moves AbioMed
Connections
The 9 strongest of 18, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mike Minogue Structural
Mike Minogue served as the former CEO and executive of AbioMed.
-
Johnson & Johnson Structural
Johnson & Johnson owns AbioMed as a subsidiary, and AbioMed's operational performance impacts J&J's growth.
-
FDA Structural
FDA regulates AbioMed, issuing alerts and classifying defects in its medical devices.
-
Department of Health & Human Services Structural
HHS investigated AbioMed regarding kickback allegations, resulting in a $3.1 million fine.
-
Massachusetts Structural
The company operates under the regulatory and operational oversight of the state government.
-
Maura Healey Operational
Maura Healey is actively challenging the CEO of AbioMed, a company she previously led.
-
Donald Trump Mentioned together
The relationship is inferred through shared political and economic contexts, specifically via a major donor connection.
-
Danvers Shared context
AbioMed is located in the town of Danvers.
Show all 9 connections
-
Charlie Baker Mentioned together
No evidence provided to establish a relationship between AbioMed and Charlie Baker.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
2 eventsAugust 2026
3 events- Abiomed is a medical device company, Maura Healey serves as the current office holder, and Mike Minogue is a candidate for state office in Massachusetts.
- Maura Healey criticized Trump administration funding while facing a Republican primary challenger, who is the CEO of AbioMed.
- Mike Minogue gained wealth from the Abiomed sale and defended his wealth in a Boston Globe article.